-

MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s kidney product known as mirokidney™ by December 31, 2025. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-miro/ to learn more.

Please note that the merger is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
855-768-1857
lewis.kahn@ksfcounsel.com

Industry:

Kahn Swick & Foti, LLC

NASDAQ:MIRO
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
855-768-1857
lewis.kahn@ksfcounsel.com

More News From Kahn Swick & Foti, LLC

CROCS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Crocs, Inc. - CROX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 24, 2025 to file lead plaintiff applications in a securities class action lawsuit against Crocs, Inc. (NasdaqGS: CROX), if they purchased the Company’s shares between November 3, 2022, and October 28 2024, inclusive (the “Class Period”). This action is pending in the United States District Court f...

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANC...

PROASSURANCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ProAssurance Corporation - PRA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ProAssurance Corporation (NYSE: PRA) to The Doctors Company. Under the terms of the proposed transaction, shareholders of ProAssurance will receive $25.00 in cash for each share of ProAssurance that they own. KSF is seeking to determine whether this consideration and the process that led to it are a...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.